# Atara Biotherapeutics, Inc.: Form 8-K, filed Jan 6, 2023

- Company: [Atara Biotherapeutics, Inc.](/companies/atra.md) (CIK 1604464)
- Form: 8-K
- Filed: 2023-01-06
- Accepted by EDGAR: Jan 6, 2023, 16:16 ET
- Period: 2022-12-30
- Accession: 0001193125-23-003555
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1604464/000119312523003555/d444758d8k.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1604464/000119312523003555/

## Items reported

- Item 2.03: New direct financial obligation

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1604464/000119312523003555/d444758d8k.htm

Filed Jan 6, 2023.
Source: SEC EDGAR, the filing index for accession 0001193125-23-003555. Last ingested by Listed: Nov 11, 2026, 02:48 ET. No prices; not investment advice.
